Oramed Pharmaceuticals Inc. — Director's Dealing 2023

Apr 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2023-04-03

Reporting Person: Mayer Arie (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-03	Common Stock	P	5009	$2.22	Acquired	23009	Direct
2023-04-04	Common Stock	P	3800	$2.21	Acquired	26809	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.17 to $2.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.